Results 1 to 10 of about 255 (97)

Opioid Use Disorder in Three Samples of the Lebanese Population: Correlation with Clinical and Genetic Factors [PDF]

European Psychiatry
Introduction Opioid Use Disorder (OUD) is a severe and recurrent condition that contributes to a global prevalence of disabilities. Accumulating evidence suggests a potential convergence of clinical and genetic factors underlying OUD. Objectives This
K. Chamoun, F. Hajj Moussa Lteif, P. Salameh, H. Sacre, R. Haddad, L. Rabbaa, B. Megarbane, A. Hajj   +7 more
doaj   +2 more sources

Investigating Sex Differences in Opioid Use Disorder Risk Factors: Insights from Cross-Section Lebanese Study Population [PDF]

European Psychiatry
Introduction Opioid use disorder (OUD) is a significant public health concern, and understanding the risk factors associated with OUD is crucial for effective prevention and management strategies. However, limited information is available regarding the
K. Chamoun, P. Salameh, H. Sacre, J. Mouawad, L. Rabbaa, B. Megarbane, A. Hajj   +6 more
doaj   +2 more sources

Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates [PDF]

Pharmaceutics, 2022
The development of animal models undergoing long-term antiretroviral treatment (ART) makes it possible to understand a number of immunological, virological, and pharmacological issues, key factors in the management of HIV infection.
Thibaut Gelé, Hélène Gouget, Nathalie Dereuddre-Bosquet, Valérie Furlan, Roger Le Grand, Olivier Lambotte, Delphine Desjardins, Aurélie Barrail-Tran   +7 more
doaj   +2 more sources

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC) [PDF]

Frontiers in Pharmacology, 2023
Introduction: Preclinical studies have demonstrated the possible role of beta-adrenergic receptors in pancreatic ductal adenocarcinoma (PDAC) tumor invasion and migration.
Antoine Le Bozec, Mathias Brugel, Zoubir Djerada, Marya Ayad, Marine Perrier, Claire Carlier, Claire Carlier, Damien Botsen, Damien Botsen, Pierre Nazeyrollas, Olivier Bouché, Florian Slimano   +11 more
doaj   +2 more sources

Evolution of Depression and Anxiety among Breast Cancer Patients: a prospective analysis using clinical, biological and genetic factors [PDF]

European Psychiatry
Introduction Numerous studies have explored the symptoms and course of depression and anxiety in breast cancer patients and identified various clinical, sociodemographic, and genetic factors associated with their evolution.
R. Khoury, R. Hachem, P. Salameh, H. Sacre, M. Bedran, L. Rabbaa, G. Chahine, J. Kattan, F. Nasr, A. Hajj   +9 more
doaj   +2 more sources

Alcohol and Sedative Use Disorders in the Lebanese Population: Role of Sleep and Psychiatric Factors [PDF]

European Psychiatry
Introduction Alcohol and sedative substance use disorders are escalating global public health challenges. Lebanon has grappled with multiple crises, including economic, healthcare, and social issues.
K. Chamoun, N. Wehbe, P. Salameh, H. Sacre, M. Atallah, J. Mouawad, L. Rabbaa, B. Megarbane, A. Hajj   +8 more
doaj   +2 more sources

Risk factors of daptomycin overexposure: a case-control study [PDF]

Antimicrobial Agents and Chemotherapy
In our institution, therapeutic drug monitoring of daptomycin is performed routinely and cases of high trough concentrations have been observed in patients without known risk factors.
Clotilde Vellat, Romain Garreau, Aurélien Millet, Catherine Piron, Laurent Bourguignon, Sandrine Roux, Tristan Ferry, Sylvain Goutelle   +7 more
doaj   +2 more sources

Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin [PDF]

Pharmaceutics, 2022
Daptomycin is a candidate for therapeutic drug monitoring (TDM). The objectives of this work were to implement and compare two pharmacometric tools for daptomycin TDM and precision dosing.
Justine Heitzmann, Yann Thoma, Romain Bricca, Marie-Claude Gagnieu, Vincent Leclerc, Sandrine Roux, Anne Conrad, Tristan Ferry, Sylvain Goutelle   +8 more
doaj   +2 more sources

A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays [PDF]

Blood Advances
: Phase 3 trials evaluating inhibitors of coagulation factor XI (FXI) and/or its activated form (FXIa) as novel anticoagulant drugs are ongoing. These agents include parenteral monoclonal antibody (abelacimab) and oral small molecules (milvexian ...
Laurie Goubeau, Emmanuel Curis, Xavier Delavenne, Isabelle Gouin-Thibault, Sophie Hodin, Adrien Genin, Julien Demagny, Fanny Menard, Dorothée Faille, Christine Mouton, Emmanuel De Maistre, Pierre Fontana, Laetitia Mauge, Annabelle Dupont, Christophe Nougier, Nathalie Hézard, Elodie Boissier, Dominique Lasne, François Grand, Paul Billoir, Agathe Herb, Corinne Frere, Sophie Voisin, Nicolas Sillamy, Claire Flaujac, François Mullier, Virginie Siguret, Georges Jourdi   +27 more
doaj   +2 more sources

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model [PDF]

Annals of Clinical Microbiology and Antimicrobials
Background Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy
Etienne Vignaud, Sylvain Goutelle, Charlotte Genestet, Jérôme Guitton, Sabine Cohen, Chloé Bourg, Aurore Durand, Laura Lebouteiller, Albin Bernard, Caroline Richet, Oana Dumitrescu, Elisabeth Hodille   +11 more
doaj   +2 more sources